This study is in progress, not accepting new patients

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

a study on Duchenne Muscular Dystrophy

Eligibility: for males ages 12-50 (full criteria)
Location: at Los Angeles, California and other locations
Dates: study started July 2022
completion around August 2026
Principal Investigator: by Perry B. Shieh, MD, PhD

Perry B. Shieh

Description

Summary

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 120 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker.

CANYON is fully enrolled; GRAND CANYON is currently enrolling.

Official Title

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of EDG-5506 on Safety, Biomarkers, Pharmacokinetics, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy

Details

The EDG-5506-201 protocol was amended to include an additional cohort thus consists of two parts.

Part 1: CANYON is a double-blind, randomized, placebo-controlled design to investigate the effect of sevasemten on the safety, pharmacokinetics, biomarkers, and functional measures. Approximately 32 adults and 18 adolescents with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, a 12-month Treatment period, followed by a 4-week follow-up period.

Approximately 32 adult participants will randomize to Cohort 1 or Cohort 2 in a 1:1 ratio then each cohort will further randomize to sevasemten or placebo in a 3:1 ratio.

Approximately 9 adolescent participants will enroll in Cohort 4 and randomize in a 2:1 ratio to sevasemten or placebo. Cohort 5 will randomize an additional 9 participants in a 2:1 ratio to either sevasemten or placebo after Cohort 4.

CANYON is now fully enrolled.

Part 2: GRAND CANYON or Cohort 6 is a double-blind, randomized, placebo-controlled design to investigate the safety and efficacy of sevasemten in adults with Becker muscular dystrophy after 18 months of treatment. Approximately 120 adults with Becker muscular dystrophy are planned to enroll in this study. This study will have up to a 4-week Screening period, an 18-month Treatment period, followed by a 4-week follow-up period.

Approximately 120 adult participants will be randomized in Cohort 6 in a 2:1 ratio either to sevasemten or placebo.

Keywords

Becker Muscular Dystrophy, Muscular Dystrophies, Duchenne Muscular Dystrophy, Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg

Eligibility

For males ages 12-50

The CANYON Study including the adolescent cohorts are fully enrolled.

GRAND CANYON eligibility is listed below.

Key Inclusion Criteria:

Adults (aged 18 to 50 years, inclusive) with a documented dystrophin mutation and phenotype consistent with Becker muscular dystrophy, and history of being ambulatory beyond 16 years of age without steroids; history of being ambulatory beyond 18 years of age with steroids.
Able to complete the 100-meter timed test in < 200 seconds with or without use of mobility aid devices.
Able to perform the North Star Ambulatory Assessment scale and achieve a score of 5 to 32, inclusive.

Key Exclusion Criteria:

Medical history or clinically significant physical examination/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes contraindications to magnetic resonance imaging such as non-compatible implanted medical devices or severe claustrophobia.
Cardiac echocardiogram ejection fraction < 40%
Forced vital capacity predicted <60% or using daytime ventilatory support
Receipt of oral corticosteroids for the treatment of BMD in the previous 6 months.
Receipt of an investigational drug within 30 days or 5 half-lives (whichever is longer) of the screening visit in the present study.

Locations

UCLA Medical Center
Los Angeles California 90095 United States
UC Irvine Medical Center
Orange California 92868 United States

Lead Scientist at UCLA

Perry B. Shieh, MD, PhD
HS Clinical Professor, Neurology, Medicine. Authored (or co-authored) 91 research publications

Details

Status: in progress, not accepting new patients
Start Date: July 2022
Completion Date: August 2026 (estimated)
Sponsor: Edgewise Therapeutics, Inc.
Links: Sponsor Website Sign up for this study
ID: NCT05291091
Phase: Phase 2 Duchenne Muscular Dystrophy Research Study
Study Type: Interventional
Participants: About 175 people participating
Last Updated: February 28, 2025

I’m interested in this study!